Naftazone is a synthetic non-steroidal anti-inflammatory drug (NSAID) that has been investigated for its potential therapeutic applications. Its synthesis involves a multi-step process, often starting from readily available starting materials. Naftazone exhibits anti-inflammatory, analgesic, and antipyretic effects, similar to other NSAIDs. Its mechanism of action involves inhibiting cyclooxygenase (COX) enzymes, which are responsible for the production of prostaglandins, mediators of inflammation and pain. While naftazone has been studied for its potential benefits in treating various inflammatory conditions, it has not been widely used clinically due to concerns regarding its side effects, including gastrointestinal toxicity and liver damage. However, ongoing research aims to investigate naftazone derivatives and optimize its therapeutic profile. Interest in naftazone has been renewed in recent years due to its potential applications in treating inflammatory bowel disease (IBD) and other chronic inflammatory conditions. The unique properties of naftazone and its derivatives make them promising candidates for developing novel and effective treatments for inflammatory diseases.'
naftazone: RN given refers to 1,2-naphthoquinone monosemicarbazone cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 71688 |
| CHEMBL ID | 2106794 |
| CHEBI ID | 134890 |
| SCHEMBL ID | 1697156 |
| MeSH ID | M0046701 |
| Synonym |
|---|
| 1,2-naphthoquinone 2-semicarbazone |
| CHEBI:134890 |
| naftazone |
| 15687-37-3 |
| mediaven (tn) |
| naftazone (inn) |
| D08243 |
| karbinon |
| haemostop injection |
| CHEMBL2106794 |
| naftazona [inn-spanish] |
| 2-semicarbazono-1(2h)-naphthalinon |
| mediavene |
| karbinone |
| naftazone [inn:ban:dcf] |
| naftazona |
| unii-15b0523p5l |
| mediaven |
| naftazonum |
| naftazonum [inn-latin] |
| einecs 239-785-1 |
| 15b0523p5l , |
| 1,2-naphthoquinone 2-semicarbazone [mi] |
| naftazone [who-dd] |
| naftazone [inn] |
| naftazone [mart.] |
| 1,2-naphthoquinone-2-semicarbazone |
| SCHEMBL1697156 |
| naftazone-d6 |
| TZGBBMBARSFJBG-UHFFFAOYSA-N |
| 2-(1-oxo-2(1h)-naphthalenylidene)-hydrazinecarboxamide |
| (e)-2-(1-oxonaphthalen-2(1h)-ylidene)hydrazine-1-carboxamide |
| DB13680 |
| haemostop injection; karbinon; karbinone; mediaven; naftazon |
| Q18575704 |
| (1-hydroxynaphthalen-2-yl)iminourea |
| procyclidinehydrochloride |
| [(1-hydroxynaphthalen-2-yl)imino]urea |
| STARBLD0009626 |
| DTXSID80864627 |
| 2-(1-oxonaphthalen-2(1h)-ylidene)hydrazine-1-carboxamide |
| {[(2e)-1-oxo-1,2-dihydronaphthalen-2-ylidene]amino}urea |
| EN300-10849282 |
| CS-0027147 |
| HY-108011 |
| mfcd00867495 |
| DTXSID001043136 |
| AKOS040748987 |
Naftazone (Etioven) is a currently used vasoprotectant drug. It is metabolized in humans by reduction and glucuronidation.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Naftazone (Etioven) is a currently used vasoprotectant drug that is metabolized in humans by reduction and glucuronidation." | ( Naftazone reduces glutamate cerebro spinal fluid levels in rats and glutamate release from mouse cerebellum synaptosomes. Bloy, C; Israel, M; Joseph, X; Mattei, C; Molgó, J, 1999) | 2.47 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " For all drugs studied, the proposed techniques are specific, reliable and sensitive enough and can be used to perform pharmacokinetic studies in human or in animal after administration of doses in the therapeutic range." | ( [Quantitative determination of drugs by in situ spectrophotometry of chromatograms for pharmacokinetic studies. I. Sulpiride and other benzamides, vincamine, naftazone (author's transl)]. Bres, J; Bressolle, F; Brun, S; Rechencq, E, 1979) | 0.46 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " The cells were dosed with these complexes at varying concentrations, and cell viability was measured by a sulforhodamine B (SRB) method." | ( The cytotoxicity and mechanisms of 1,2-naphthoquinone thiosemicarbazone and its metal derivatives against MCF-7 human breast cancer cells. Afrasiabi, Z; Chen, J; Huang, YW; Liu, G; Ma, Y; Padhye, S; Sinn, E, 2004) | 0.32 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (26.32) | 18.7374 |
| 1990's | 8 (42.11) | 18.2507 |
| 2000's | 1 (5.26) | 29.6817 |
| 2010's | 4 (21.05) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (39.93) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 4 (21.05%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 15 (78.95%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||